Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

JAK2 fusion genes are rare but recurrent abnormalities associated with diverse, clinically heterogeneous hematologic malignancies. Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN). Ruxolitinib-treated Ba/F3...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chase, Andrew, Bryant, Catherine, Score, Joannah, Haferlach, Claudia, Grossmann, Vera, Schwaab, Juliana, Hofmann, Wolf-Karsten, Reiter, Andreas, Cross, Nicholas C.P.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2013
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3659945/
https://ncbi.nlm.nih.gov/pubmed/22875628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.067959
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados